To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
New FLEXYTE® Protease Assays Enable Information-Rich Output, Miniaturization and Multiplexing
Read time: Less than a minute
Almac launches FLEXYTE® protease assay platform - the next step in utilization of fluorescent lifetime technology - at the 2010 Society for Biomolecular Sciences (SBS) meeting in Phoenix (11-15 April).
The new FLEXYTE® protease assays follow on from the great success of FLEXYTE® protein kinase assays launched in 2009. FLEXYTE® protease assays harness the potential of fluorescence lifetime technology.
Avoiding radioactivity, antibodies and associated costs, fluorescence lifetime technology enables homogenous, and reliable assays with minimized interference from problem compounds, and will allow miniaturization, and multiplexing, while maintaining an information-rich output.
FLEXYTE® protease assays are based on labelled peptide substrates which have been developed for a variety of proteases. The generic peptide approach enables FLEXYTE® protease assays to be configured for a broad range of proteases. Almac will provide a custom assay development service for any protease of interest to customers.
Commenting on the launch of FLEXYTE® protease assays, Almac Sciences’ President and Managing Director, Stephen Barr said: “FLEXYTE® protease assays represent the next step in utilization of fluorescent lifetime technology to produce more robust, reliable and efficient assays in therapeutically important target classes.”
Almac will be exhibiting at the SBS meeting and will be available to provide more information on FLEXYTE® protease and protein kinase assays at booth 229.
The new FLEXYTE® protease assays follow on from the great success of FLEXYTE® protein kinase assays launched in 2009. FLEXYTE® protease assays harness the potential of fluorescence lifetime technology.
Avoiding radioactivity, antibodies and associated costs, fluorescence lifetime technology enables homogenous, and reliable assays with minimized interference from problem compounds, and will allow miniaturization, and multiplexing, while maintaining an information-rich output.
FLEXYTE® protease assays are based on labelled peptide substrates which have been developed for a variety of proteases. The generic peptide approach enables FLEXYTE® protease assays to be configured for a broad range of proteases. Almac will provide a custom assay development service for any protease of interest to customers.
Commenting on the launch of FLEXYTE® protease assays, Almac Sciences’ President and Managing Director, Stephen Barr said: “FLEXYTE® protease assays represent the next step in utilization of fluorescent lifetime technology to produce more robust, reliable and efficient assays in therapeutically important target classes.”
Almac will be exhibiting at the SBS meeting and will be available to provide more information on FLEXYTE® protease and protein kinase assays at booth 229.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
